Literature DB >> 16728630

Molecular imaging in cancer.

Ralph Weissleder1.   

Abstract

Medical imaging technologies have undergone explosive growth over the past few decades and now play a central role in clinical oncology. But the truly transformative power of imaging in the clinical management of cancer patients lies ahead. Today, imaging is at a crossroads, with molecularly targeted imaging agents expected to broadly expand the capabilities of conventional anatomical imaging methods. Molecular imaging will allow clinicians to not only see where a tumor is located in the body, but also to visualize the expression and activity of specific molecules (e.g., proteases and protein kinases) and biological processes (e.g., apoptosis, angiogenesis, and metastasis) that influence tumor behavior and/or response to therapy. This information is expected to have a major impact on cancer detection, individualized treatment, and drug development, as well as our understanding of how cancer arises.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728630     DOI: 10.1126/science.1125949

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  281 in total

1.  Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Irma Soldevilla-Gallardo; Sevastian S Medina-Ornelas; Cynthia Villarreal-Garza; Enrique Bargalló-Rocha; Claudia Hs Caro-Sánchez; Rodrigo Hernández-Ramírez; Enrique Estrada-Lobato
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Authors:  Mingqian Tan; Susan M Burden-Gulley; Wen Li; Xueming Wu; Daniel Lindner; Susann M Brady-Kalnay; Vikas Gulani; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

Review 3.  Chlorotoxin-conjugated nanoparticles as potential glioma-targeted drugs.

Authors:  Yuejun Fu; Na An; Ke Li; Yali Zheng; Aihua Liang
Journal:  J Neurooncol       Date:  2011-11-23       Impact factor: 4.130

4.  Feasibility study of near-infrared fluorescence tomography using a positron emission tomograph equipped with depth-of-interaction PET detectors.

Authors:  Hideaki Tashima; Takashi Obi; Taiga Yamaya; Hideo Murayama; Keishi Kitamura; Ichiro Oda; Masahiro Yamaguchi; Nagaaki Ohyama
Journal:  Radiol Phys Technol       Date:  2009-06-30

Review 5.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  Quantitative fluorescence tomography using a trimodality system: in vivo validation.

Authors:  Yuting Lin; William C Barber; Jan S Iwanczyk; Werner W Roeck; Orhan Nalcioglu; Gultekin Gulsen
Journal:  J Biomed Opt       Date:  2010 Jul-Aug       Impact factor: 3.170

7.  Synthesis and photo-physical characteristics of ESIPT inspired 2-substituted benzimidazole, benzoxazole and benzothiazole fluorescent derivatives.

Authors:  Vikas S Padalkar; Abhinav Tathe; Vinod D Gupta; Vikas S Patil; Kiran Phatangare; N Sekar
Journal:  J Fluoresc       Date:  2011-09-29       Impact factor: 2.217

Review 8.  Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer.

Authors:  Melodi J Whitley; Ralph Weissleder; David G Kirsch
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

Review 9.  Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery.

Authors:  Laura Beretta
Journal:  Cancer Lett       Date:  2009-02-15       Impact factor: 8.679

Review 10.  Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.

Authors:  Shreya Goel; Christopher G England; Feng Chen; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2016-08-09       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.